Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab for refractory myasthenia gravis
ChiCTR2400093064Phase 3Not yet recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Nov 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of blinatumomab in myasthenia gravis (MG), sponsored by Xinqiao Hospital. Primary endpoints: Change in Myasthenia Gravis Activities of Daily Living score at week 12, Steroid dosage change and 1 more. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
blinatumomab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on ChiCTR2400093064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093064.